

# Datasheet: HCA176P

Description:	HUMAN ANTI TRASTUZUMAB:HRP
Specificity:	TRASTUZUMAB
Other names:	HERCEPTIN®
Format:	HRP
Product Type:	Monoclonal Antibody
Clone:	AbD16712_hlgG1
Isotype:	lgG1
Quantity:	0.1 mg

## **Product Details**

Applications	This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further					
	information. For general protocol recommendations, please visit <u>www.bio-</u> rad-antibodies.com/protocols.					
		Yes	No	Not Determined	Suggested Dilution	
	ELISA	-				
	Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as					
	a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.					
Product Form	Human IgG1 antibody selected from the HuCAL phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.					
Preparation	Purified IgG prepared by	affinity ch	romatogr	aphy on Protein A		
Source	НКВ-11					
Buffer Solution	Phosphate buffered salin	е				
Preservative Stabilisers	0.0095% MIT					
Approx. Protein Concentrations	Antibody concentration 1	.0 mg/ml				
Immunogen	Trastuzumab (Herceptin@	3)				

Specificity	Human anti Trastuzumab, clone AbD16712_hlgG1, is an anti-idiotypic antibody that specifically recognizes the humanized monoclonal antibody drug trastuzumab, also known as Herceptin®. Clone AbD16712_hlgG can be used to measure the levels of trastuzumab and biosimilar products using bioanalytical assays.
	In the HRP-conjugated format clone AbD16712_hIgG1 is ideal for use as a detection antibody in pharmacokinetic (PK) assays. It is a fully human antibody and therefore may also be used as a calibrator in immune response assays to measure the anti-drug-antibody (ADA) response in patient sera.
	Trastuzumab is a drug used in the treatment of HER2 positive breast cancer and other HER2 overexpressing cancers including HER2-positive metastatic cancers of the gastrointestinal tract. Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells
	View a summary of all anti-trastuzumab antibodies.
Affinity	The intrinsic affinity of the monovalent form of this antibody in an unconjugated format is 0.4 nM as measured by real time, label-free molecular interaction analysis on immobilized trastuzumab.
ELISA	This product may be used as a detection reagent in a sandwich ELISA together with <u>HCA169</u> as the capture reagent. Protocol: <u>PK bridging ELISA to measure free drug</u> .
References	<ol> <li>Kashiwagi, N. <i>et al.</i> (2017) Method for measuring anti-drug antibody <u>US Patent</u> <u>Application US20170315118</u></li> <li>Iwamoto, N. <i>et al.</i> (2018) Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis. <u>Anal Biochem. 540-541: 30-7.</u></li> <li>Arceo, T. <i>et al.</i> (2025) Impact of positive control binding properties on anti-drug antibody assay performance. <u>Bioanalysis. June 12 : 1-6 [Epub ahead of print]</u></li> </ol>
Storage	This product is shipped frozen. When ready to use, thaw and aliquot the sample as needed. Store aliquots at -70°C, if available, otherwise store at -20°C. It is not recommended to keep aliquots at 4°C for more than one week.
Guarantee	12 months from date of despatch
Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Health And Safety Information	Material Safety Datasheet documentation #20479 available at: https://www.bio-rad-antibodies.com/SDS/HCA176P 20479

Licensed Use	For <i>in vitro</i> research purposes and for commercial applications for the provision of <i>in vitro</i> testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.	
Regulatory	For research purposes only	
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <u>HuCAL Antibodies Technical Manual</u> .	

### **Related Products**

#### **Recommended Useful Reagents**

HUMAN ANTI TRASTUZUMAB (HCA166) HUMAN ANTI TRASTUZUMAB (HCA169) HISPEC ASSAY DILUENT (BUF049A)

North & South Tel: +1 800 265 7376 Worldwide America Fax: +1 919 878 3751 Email: antibody\_sales\_us@bio-rad.com

Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody\_sales\_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody\_sales\_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M438557:250516'

#### Printed on 17 Jun 2025

© 2025 Bio-Rad Laboratories Inc | Legal | Imprint